急性、亚急性与迁延期危重症中CRH刺激后ACTH与皮质醇反应:一项随机、双盲、安慰剂对照交叉队列研究
本研究为随机、双盲、安慰剂对照交叉队列研究,比较急性(ICU第3-6天)、亚急性(ICU第7-16天)、迁延期(ICU第17-28天)各40例匹配患者及20例健康对照对100 µg IV CRH与安慰剂的ACTH反应。患者平均ACTH正常(25.5 ± 1.6 vs 健康者24.8 ± 3.6 pg/ml,P = 0.54)但游离皮质醇升高(3.11 ± 0.27 vs 0.58 ± 0.05 µg/dl,P < 0.0001)。急性期ACTH反应正常(5149 ± 848 vs 4120 ± 688 pg/mL min,P = 0.77),亚急性期(2333 ± 387 pg/mL min,P = 0.01)与迁延期(2441 ± 685 pg/mL min,P = 0.001)反应降低,与脓毒症/脓毒性休克或死亡风险无关。结论提示迁延期ACTH反应受抑符合高游离皮质醇反馈抑制而非下丘脑/垂体细胞损伤。
要点
- 危重症患者平均ACTH正常(25.5 ± 1.6 pg/ml)但游离皮质醇显著升高(3.11 ± 0.27 vs 健康者0.58 ± 0.05 µg/dl,P < 0.0001)。
- 急性期(ICU第3-6天)ACTH对100 µg IV CRH反应正常(5149 ± 848 vs 健康者4120 ± 688 pg/mL min,P = 0.77)。
- 亚急性期(ICU第7-16天)ACTH反应降低至2333 ± 387 pg/mL min(P = 0.01),迁延期(ICU第17-28天)降低至2441 ± 685 pg/mL min(P = 0.001)。
- ACTH反应降低与是否合并脓毒症/脓毒性休克或死亡风险无关。
- 迁延期ACTH反应受抑符合高游离皮质醇反馈抑制,而非下丘脑和/或垂体细胞损伤。
适用人群与场景
- 急性期队列:ICU第3-6天的危重症患者40例;亚急性期队列:ICU第7-16天40例;迁延期队列:ICU第17-28天40例;均为匹配患者。
- 健康对照组:20例人口学匹配的健康受试者。
处置流程与药物剂量
- CRH 100 µg静脉注射,与安慰剂在连续两天内按随机顺序给药,每次注射后135分钟内反复采血。
- 以CRH刺激后ACTH曲线下面积减去安慰剂对应面积作为ACTH反应值。
研究设计与关键结果
- 研究类型:随机、双盲、安慰剂对照交叉队列研究;样本量:3个危重症队列各40例匹配患者,共120例,另20例健康对照。
- 患者平均血浆ACTH正常:25.5 ± 1.6 vs 健康者24.8 ± 3.6 pg/ml,P = 0.54;游离皮质醇升高:3.11 ± 0.27 vs 0.58 ± 0.05 µg/dl,P < 0.0001。
- CRH/安慰剂注射顺序不影响ACTH反应,故结果合并分析。
- 急性期ACTH反应正常:5149 ± 848 vs 健康者4120 ± 688 pg/mL min,P = 0.77。
- 亚急性期ACTH反应降低:2333 ± 387 pg/mL min,P = 0.01;迁延期降低:2441 ± 685 pg/mL min,P = 0.001;均与脓毒症/脓毒性休克或死亡风险无关。
证据类型、等级与局限
- 证据类型:随机、双盲、安慰剂对照交叉队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,迁延期危重症中ACTH对CRH反应受抑符合高游离皮质醇反馈抑制,而非下丘脑和/或垂体细胞损伤。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Low plasma ACTH in critically ill patients may be explained by shock/inflammation-induced hypothalamus-pituitary damage or by feedback inhibition exerted by elevated plasma free cortisol. One can expect augmented/prolonged ACTH-responses to CRH injection with hypothalamic damage, immediately suppressed responses with pituitary damage, and delayed decreased responses in prolonged critical illness with feedback inhibition.
METHODS: This randomized, double-blind, placebo-controlled crossover cohort study, compared ACTH responses to 100 µg IV CRH and placebo in 3 cohorts of 40 matched patients in the acute (ICU-day 3-6), subacute (ICU-day 7-16) or prolonged phase (ICU-day 17-28) of critical illness, with 20 demographically matched healthy subjects. CRH or placebo was injected in random order on two consecutive days. Blood was sampled repeatedly over 135 min and AUC responses to placebo were subtracted from those to CRH.
RESULTS: Patients had normal mean ± SEM plasma ACTH concentrations (25.5 ± 1.6 versus 24.8 ± 3.6 pg/ml in healthy subjects, P = 0.54) but elevated free cortisol concentrations (3.11 ± 0.27 versus 0.58 ± 0.05 µg/dl in healthy subjects, P < 0.0001). The order of the CRH/placebo injections did not affect the ACTH responses, hence results were pooled. Patients in the acute phase of illness had normal mean ± SEM ACTH responses (5149 ± 848 pg/mL min versus 4120 ± 688 pg/mL min in healthy subjects; P = 0.77), whereas those in the subacute (2333 ± 387 pg/mL min, P = 0.01) and prolonged phases (2441 ± 685 pg/mL min, P = 0.001) were low, irrespective of sepsis/septic shock or risk of death.
CONCLUSIONS: Suppressed ACTH responses to CRH in the more prolonged phases, but not acute phase, of critical illness are compatible with feedback inhibition exerted by elevated free cortisol, rather than by cellular damage to hypothalamus and/or pituitary.
参考来源
- Peeters B, Meersseman P, Vander Perre S, et al. ACTH and cortisol responses to CRH in acute, subacute, and prolonged critical illness: a randomized, double-blind, placebo-controlled, crossover cohort study. Intensive Care Med. 2018. PMID: 30374692. doi:10.1007/s00134-018-5427-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。